CST3 and early-onset autosomal dominant Alzheimer disease: Because Cathepsin B has been nominated as a promising therapeutic target to treat Alzheimer’s disease [17], future therapies directed towards correcting chromatin accessibility at respective CREs elements, like those for Ctsb and Cst3, may be able to limit potential side effects from diseases involving aberrant protein expression.